191 related articles for article (PubMed ID: 26502694)
61. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
Rea TH; Sieling PA
Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
[TBL] [Abstract][Full Text] [Related]
62. Erythema necroticans exhibiting transepidermal migration of lepra bacilli as a probable source of infection to other family members.
Ghosh SK; Ghosh A; Agarwal M
Int J Dermatol; 2016 Jan; 55(1):e42-5. PubMed ID: 26518468
[No Abstract] [Full Text] [Related]
63. Erythema nodosum leprosum necroticans in a child--an unusual manifestation.
Pandhi D; Mehta S; Agrawal S; Singal A
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):122-6. PubMed ID: 16830655
[TBL] [Abstract][Full Text] [Related]
64. Erythema Necroticans - A Case Report.
Mehta N; Ramachandran R; Srikanth S
Indian J Lepr; 2016 Sep; 87(4):255-257. PubMed ID: 29762955
[TBL] [Abstract][Full Text] [Related]
65. Clinical and histological discrepancies in diagnosis of ENL reactions classified by assessment of acute phase proteins SAA and CRP.
Hussain R; Lucas SB; Kifayet A; Jamil S; Raynes J; Uqaili Z; Dockrell HM; Chiang TJ; McAdam KP
Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):222-30. PubMed ID: 7602217
[TBL] [Abstract][Full Text] [Related]
66. Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day.
Putinatti MS; Lastória JC; Padovani CR
An Bras Dermatol; 2014; 89(2):266-72. PubMed ID: 24770503
[TBL] [Abstract][Full Text] [Related]
67. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
68. Localized and persistent erythema nodosum leprosum - a rare variant?
Prabhu S; Rao R; Sripathi H; Rao L; Singh R
Dermatol Online J; 2008 Mar; 14(3):16. PubMed ID: 18627717
[TBL] [Abstract][Full Text] [Related]
69. Leprosy: an uncommon infection with varied presentations.
van Hal SJ; Hudson BJ
Med J Aust; 2006 May; 184(9):473-4. PubMed ID: 16646750
[No Abstract] [Full Text] [Related]
70. [Leprosy and the testis].
Rodríguez G; Abaúnza MC; Vargas EJ; López F
Biomedica; 2012; 32(1):13-22. PubMed ID: 23235783
[TBL] [Abstract][Full Text] [Related]
71. [Leprosy with an unusual course].
Desenfants A; Huguon E; Polfrit Y; Crouzat M; Rouleau V; Chassot V; Besson-Leaud L; Missotte I
Arch Pediatr; 2012 Nov; 19(11):1182-6. PubMed ID: 23037580
[TBL] [Abstract][Full Text] [Related]
72. [Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum].
Ishii N; Ishida Y; Okano Y; Ozaki M; Gidoh M; Kumano K; Goto M; Nogami R; Hatano K; Yamada A; Yotsu RR
Nihon Hansenbyo Gakkai Zasshi; 2011 Sep; 80(3):275-85. PubMed ID: 21941834
[TBL] [Abstract][Full Text] [Related]
73. Elevated platelet counts and thrombocytosis in erythema nodosum leprosum.
Rea TH
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):167-73. PubMed ID: 12483964
[TBL] [Abstract][Full Text] [Related]
74. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
[TBL] [Abstract][Full Text] [Related]
75. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
Fabi SG; Hill C; Witherspoon JN; Boone SL; West DP
J Drugs Dermatol; 2009 Aug; 8(8):765-9. PubMed ID: 19663116
[TBL] [Abstract][Full Text] [Related]
76. Two atypical presentations of lepra reactions.
Pathania V; Shelly D; Shankar P; Matharu YS; Baveja V
Int J Mycobacteriol; 2018; 7(4):390-393. PubMed ID: 30531041
[TBL] [Abstract][Full Text] [Related]
77. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.
Sampaio EP; Kaplan G; Miranda A; Nery JA; Miguel CP; Viana SM; Sarno EN
J Infect Dis; 1993 Aug; 168(2):408-14. PubMed ID: 8335978
[TBL] [Abstract][Full Text] [Related]
78. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial.
de Barros B; Lambert SM; Shah M; Pai VV; Darlong J; Rozario BJ; Alinda MD; Sales AM; Doni S; Hagge DA; Shrestha D; Listiawan MY; Yitaye AM; Nery JAC; Neupane KD; Dias VLA; Butlin CR; Nicholls PG; Lockwood D; Walker SL
BMJ Open; 2020 Nov; 10(11):e037700. PubMed ID: 33203627
[TBL] [Abstract][Full Text] [Related]
79. Erythema nodosum leprosum: reactional leprosy.
Cuevas J; Rodríguez-Peralto JL; Carrillo R; Contreras F
Semin Cutan Med Surg; 2007 Jun; 26(2):126-30. PubMed ID: 17544965
[TBL] [Abstract][Full Text] [Related]
80. Target/therapies for chronic recurrent erythema nodosum leprosum.
Thangaraju P; Varthya SB; Venkatesan S
Indian J Pharmacol; 2020; 52(3):222-226. PubMed ID: 32874007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
